leisure time -WSS

leisure time

author：explore 2025-09-29 18:18:26 - browse：5733

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： VC firm General Catalyst wants to buy a health system

focus

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

Readout Newsletter: Merck, Vertex, and Viking updates

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Sana to lay off nearly a third of staff, de

Stroke deaths set to near 10 million globally by 2050

Bristol 'take

leisure time

leisure time

Wikipedia

Supreme Court strikes down use of affirmative action

Vertex Pharmaceuticals may move headquarters in Boston

The high cost of giving birth even with insurance

States should stop sabotaging methadone treatment reform

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Merck, Vertex, and Viking updates

Medicare details structure of new drug price negotiation program

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

The cancer drug shortage isn’t new — and neither are the solutions

Sana to lay off nearly a third of staff, de

hotspot

Histogen: Failed biotech offers rare public look inside

Readout Newsletter: Merck, Vertex, and Viking updates

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Liquid biopsy for lung cancer is launched by Delfi

Food as medicine: Medically tailored meals may get standardized

Abortion pill Supreme Court ruling could impact entire drug industry

focus

hotspot

knowledge

leisure time